Drug intelligence / Profile preview

VG-302

Development stage: Preclinical
Lead developer: Virogin Biotech
Modality: Oncolytic Viruses → Oncolytic Therapeutics

Overview

VG-302 is a drug candidate initially developed by Virogin Biotech Ltd. It is currently in the discovery phase of its research and development, with its primary therapeutic area being neoplasms, specifically solid tumors.

Targets

IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on VG-302.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VG-302.

Explore the full profile